Eosinophilic granulomatosis with polyangiitis
Conditions
Interventions
None listed
Sponsors
Takeshita Yukio
GlaxoSmithKline K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients =<30 day after onset of EGPA neuropathy. 2) Patients who treated with steroid-pulse therapy (3 days) during the acute phase of EGPA neuropathy and shown no complete remission in EGPA neuropathy. 3) Patients who meet the American Society of Rheumatology EGPA classification criteria or American College of Rheumatology/European League Against Rheumatism EGPA classification criteria. 4) Patients aged 20 years or older at the time of onset of EGPA neuropathy. 5) Regardless of gender. 6) Patients who gave informed consent to participate in the study by the patient or the legally acceptable representative after receiving adequate explanation for their participation in the study.
Exclusion criteria
Exclusion criteria: 1) Patients being treated with mepolizumab 2) Patients who received steroid-pulse therapy (3 days) in the acute phase of EGPA neuropathy and had complete EGPA neuropaty resolution. 3) Life-threatening patients 4) Patients who were judged inappropriate by principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of peripheral nerve recovery rate, electrical diagnosis rate of peripheral nerve recovery, peripheral blood eosinophil count, and relapse rate with previous results. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of test items other than primary endpoints and safety with previous results. | — |
Contacts
Public ContactYukio Takeshita
Yamaguchi University Faculty of Medicine
Outcome results
None listed